Explore Our Biomarker Menu

Biological or Clinical Significance:

Bone morphogenetic protein (BMP)9 is a circulating growth factor that is part of the TGF-b superfamily and is an essential regulator of vascular endothelial homeostasis.

BMP9 upregulates TLR4 expression in human endothelial cells and BMP9 pretreatment synergistically increases human neutrophil recruitment to LPS-stimulated human endothelial monolayers in an in vitro flow adhesion assay. BMP9 alone doesnot induce neutrophil recruitment to the endothelium. E-selectin and VCAM-1, not ICAM-1, are upregulated in response to BMP9 in LPS-stimulated human endothelial cells. Small interfering RNA knockdown of activin receptor–like kinase 1 inhibits the BMP9-induced expression of TLR4 and VCAM-1 and inhibits BMP9-induced human neutrophil recruitment to LPS-stimulated human endothelial cells.

BMP9 treatment also increases leukocyte recruitment within the pulmonary circulation in a mouse acute endotoxemia model. Although BMP9 alone does not influence leukocyte recruitment, it primes the vascular endothelium to mount a more intense response when challenged with LPS through an increase in TLR4, E-selectin, and VCAM-1 and ultimately through enhanced leukocyte recruitment.





Human Serum


Experienced Running


0.304 pg/mL




Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.